Phase 2 Trial of Inpegsomatropin for Adult Growth Hormone Deficiency
Summary
A Phase 2a clinical trial (NCT07551804) evaluating the safety, pharmacokinetic profile, and efficacy of Inpegsomatropin Injection in adults with growth hormone deficiency has been registered. The multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled study will enroll 36 adult participants sequentially in ascending dose cohorts with a 3:1 randomization ratio within each cohort. The trial intervention is Inpegsomatropin Injection compared to placebo.
“A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a new Phase 2 clinical trial on ClinicalTrials.gov for Inpegsomatropin Injection in adult growth hormone deficiency patients. The trial is designed as a multiple-dose, dose-escalation study enrolling 36 participants across ascending dose cohorts with 3:1 randomization to active treatment versus placebo.
For pharmaceutical sponsors and clinical investigators, this registry entry provides visibility into the competitive landscape for growth hormone deficiency therapies. Sponsors developing similar products should note the trial design parameters and enrollment targets when planning their own development programs.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
â ClinicalTrials.gov Studies
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
Phase 2 NCT07551804 Kind: PHASE2 Apr 27, 2026
Abstract
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase â Ħa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose cohorts, and within each dose cohort, participants will be randomized in a 3:1 ratio.
Conditions: Adult Growth Hormone Deficiency
Interventions: Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection, Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection, Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.